PRGO
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when PERRIGO Co plc publishes a filing, an earnings call transcript or a press release.
Get PRGO alertsEduardo Bezerra is recorded as CFO at PERRIGO Co plc (PRGO). The newest filing on record that lists Eduardo Bezerra as CFO at PERRIGO Co plc (PRGO) is dated March 20, 2026. Earlier roles on record: CFO at Del Monte Corp (DMC) until March 31, 2022. The proxy statement of PERRIGO Co plc reports total compensation of $3,669,615 for Eduardo Bezerra in fiscal 2025, including a base salary of $777,777. Disclosed compensation is on record for 7 fiscal years. Eduardo Bezerra has spoken on 24 earnings calls and 2 other investor events across 2 companies, most recently for PERRIGO Co plc on November 4, 2026. Those appearances were for PERRIGO Co plc (PRGO) and Del Monte Corp (DMC). PERRIGO Co plc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other companies whose calls Eduardo Bezerra spoke on are classified in the Consumer Defensive sector. Other leadership on record at PERRIGO Co plc includes Albert A. Manzone (CEO and Board Member), Patrick Lockwood-Taylor (CEO), Charles Atkinson (General Counsel) and 7 others.
“Other than for references to net sales, my comments will focus on adjusted non-GAAP results, unless otherwise noted. Turning to our Q3 results, starting with the top line.”
“So we expect 80% of these to take place in 26 and the remaining 20 in 2027. So we have already delivered between Q1 and Q2 a portion of that.”
“And our new reporting segments include self-care, turning to our results starting with the top line. Core net sales declined 8.3% year-over-year, driven by software consumption, primarily in-coffing calls, and retailer inventory stocking in the self-care segment.”
“And our new reporting segments include self-care, turning to our results starting with the top line. Core net sales declined 8.3% year-over-year, driven by software consumption, primarily in-coffing calls, and retailer inventory stocking in the self-care segment.”
“Before we get into the details of our financials, I want to note that our 2025 gap results include non-cash accounting impact, including a goodwill impairment charge of $1.3 billion.”
Start not stated–present
Last confirmed March 20, 2026
Start not stated–2022-03-31
PRGO
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
DMC
Farm Products · Consumer Defensive
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | PERRIGO Co plc (PRGO) | EVP, CFO | $777,777 | $3,669,615 |
| 2024 | PERRIGO Co plc (PRGO) | EVP, CFO | $755,300 | $3,239,796 |
| 2023 | PERRIGO Co plc (PRGO) | EVP, CFO | $721,000 | $3,051,392 |
| 2022 | Del Monte Corp (DMC) | Former SVP, CFO | $121,250 | $130,379 |
| 2022 | PERRIGO Co plc (PRGO) | EVP, CFO | $437,500 | $3,072,021 |
| 2021 | Del Monte Corp (DMC) | Former SVP, CFO | $483,135 | $880,234 |
| 2020 | Del Monte Corp (DMC) | Former SVP, CFO | $402,596 | $804,013 |
| 2019 | Del Monte Corp (DMC) | SVP and CFO | $302,678 | $682,527 |